What stage does Forepont Capital Partners invest at?

Forepont Capital Partners invests at the Pre-Seed, Seed, Series A, Series B, Series C, Late Stage stages.

Where is Forepont Capital Partners located?

Forepont Capital Partners is headquartered in New York, US.

Does Forepont Capital Partners lead rounds?

Yes, Forepont Capital Partners leads investment rounds.

Forepont Capital Partners

Venture capital

New York · Pre-Seed–Late Stage · 24 people tracked

Also known as FOREPONT CAPITAL LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Forepont Capital Partners invests in early-stage companies before their inflection point, targeting ventures with the potential to improve the lives of millions. Its focus centers on 'Brain AI' — artificial intelligence that advances neuroscience — and applications of that technology across healthcare, safety, education, defense, and device control. The firm also backs biological frameworks that improve AI performance and efficiency and unlock new capabilities. Forepont typically retains a board seat in most portfolio companies, sizing its positions to maintain influence, and supports its companies scientifically, technologically, and strategically through its expertise and network.

Invests inAI & Machine Learning Biotech Deep Tech Defense Tech EdTech Healthtech Medical DevicesEuropeFranceNew YorkUnited Arab EmiratesUnited KingdomUnited States

Source: firm website, verified Aug 11, 2026.

Stage

Pre-Seed–Late Stage

New York, New York, US

Leads rounds

Leads

Instruments

Equity

Founded

2017

Private fund assets

$89.1M

VC funds

Tracked investments

Team · 24 people

from the firm's website & public directories

Eric M. Attias· Managing Partner, Bio&Med Fund; Co-Managing Partner, Brain AI Fund; Founder· New York

Eric M. Attias founded Forepont in 2017 and serves as managing partner of its Bio&Med Fund and co-managing partner of its Brain AI Fund. He has an investment and company-building background that includes early investments in Synchron and Precision Neuroscience, as well as building, acquiring, and selling companies such as Nexar (sold to UBP) and stakes tied to Allianz's AAAM and Ermitage. He previously managed a large alternative investment company and holds degrees in computer science (neural networks), engineering, and business administration.

e•••@forepont.comreveal

Julien Tizot· General Partner· Paris, Francein

Julien Tizot is Chief Investment Officer at Aras SFO. With 20 years of investment and management experience, he has worked as an institutional investor across public and private markets for insurance companies and a single family office, as a general partner investing in early-stage startups from seed to Series C in the US and Europe, and as CEO of both a biotech company and an investment advisory firm. He serves as a board member and advisor to companies and governments.

David Putrino· Venture Partner

Doug Weber· Venture Partner

A. Cheikh Lahlou· Senior Advisor

Ali Cheikh Lahlou· Paris

David Norton· Board member

Doug Siekierski· New York

Dr. Ismail Kola· Senior Advisor

Dr. Philippe Schaison· Board member

Geoff Kalish· Board member

Giulia Mortilla· New York

K. Alataris· Palo Alto

Holds a PhD.

Karine Montluc· New York

Laurent Bouyoux· Board member

Michel Vounatsos· Senior Advisor

Per Wold-Olsen· Board member

Philippe Schaison· Board member

Bruce Greenberg· Chief Financial Officer· New York

Bruce Greenberg has served as Chief Financial Officer at Forepont since June 2017. Earlier, in 2002, he co-founded a Commodity Trading Advisor focused on commodities and currencies. He holds a BS in Accounting from Brooklyn College, CUNY, and earned his CPA certificate in 1991; he is a member of the AICPA and NYSSCPA.

b•••@forepont.comreveal

Frederic Batoua· Partner· London

Frederic Batoua joined Forepont in 2020 and leads the firm's Investment Research. He has over 20 years of experience analyzing European and U.S. companies, having worked as a portfolio manager and analyst on both the buy and sell side at hedge funds and investment banks. He holds a Master's degree in Financial Analysis & Investment Management from Audencia Business School.

f•••@forepont.comreveal

Guillaume Bouyoux· Vice President· New York

Guillaume Bouyoux is a Vice President at Forepont, which he joined in 2023 following his MBA. He previously worked as a financial analyst at Neoxam. He holds an MBA from NYU Stern School of Business, an MS in Finance from Washington University in St. Louis, and a BS in Applied Mathematics from Université Paris Dauphine-PSL.

g•••@forepont.comreveal

Ismail Kola· Senior Advisor

Dr. Ismail Kola joined Forepont in April 2019 as a senior advisor, following a career in senior executive roles across the pharmaceutical industry. He previously served as CSO of UCB, held senior research leadership positions at Schering-Plough, Merck, and Pharmacia, and was a Professor of Human Molecular Genetics at Monash University Medical School. He holds academic appointments at Oxford, Washington University, Monash, the Karolinska Institute, and Cambridge, and earned a Ph.D. in Medicine from the University of Cape Town.

i•••@forepont.comreveal

Louis Moulin· Vice President· Paris

Louis Moulin is a Vice President at Forepont, having joined in 2020 as an analyst after completing an internship with the firm. He holds a Master in Management and a BBA in Finance and Entrepreneurship, both from EMLYON Business School.

l•••@forepont.comreveal

Philippe Louisadat· Partner· Paris

Philippe Louisadat joined Forepont in 2021, where he oversees business development. He previously served as Head of Distribution at Rothschild & Co and Head of Distribution at Oddo Asset Management. He studied at the Institut Supérieur de Gestion and holds an AMF Certification.

p•••@forepont.comreveal

What they invest in

from 10 of 13 portfolio companies

Medical Devices ×8Biotech ×6Deep Tech ×4Digital Health ×4Healthtech ×4AI & Machine Learning ×2Data & Infrastructure ×1Enterprise Software ×1

HQs:France×5United States×3

Investments · 13 tracked

founders shown can be your intro path

By year:2021 · 1 2018 · 12 dated

AlterDiagalterdiag.comin 𝕏

AlterDiag is a diagnostics company founded by executives with backgrounds in immunology R&D and business strategy.

BiotechDigital HealthHealthtechMedical DevicesParis, FR

Karine(Founder)Cédric(Founder)

Ansell A/Sansellatx.comin

Ansella Therapeutics develops novel vaginal formulations for women's health conditions using biomimetic materials science and biomedical engineering, focused on treating menopause, vaginal dryness, dyspareunia, vaginal mucositis, endometriosis, uterine fibroids, and vaginal infections.

BiotechFemTechMedical DevicesAustin, US

Basecamp Vascularbasecampvascular.comin 𝕏

BCV Systems develops a mechatronic guidewire system using shape memory alloy actuators to optimize navigation during minimally invasive endovascular procedures for stroke treatment and other vascular interventions.

Deep TechHealthtechMedical DevicesParis, FR

Dr Raphaël Blanc(President)Jean-Baptiste Cazeneuve(CTO, Mechatronic Engineer)Jérôme Szewczyk(Researcher at the Institute of Intelligent Systems and Robotics ISIR, Professor at Sorbonne University)Michel Boulaire(Strategy consultant)

Bay Bridge Digitalbaybridgedigital.comJun 2018

BayBridgeDigital is a Salesforce consulting firm that helps retailers, healthcare, real estate, education, and hospitality companies with digital transformation through CRM implementation, data management, and cloud platform integration.

Data & InfrastructureEnterprise SoftwareSaaSNew York, US

Guy Jerusalmi(Executive Officer)ALAIN ATTIAS(Executive Officer)

Becare Linkbecarelink.comin

BeCareLink builds AI-enhanced mobile platforms for remote neurological assessments, allowing patients to monitor their neurological health from home while helping clinicians and researchers track disease progression.

AI & Machine LearningDigital HealthHealthtech

Lawrence Rubin(Co-founder)Charisse D. Litchman(Co-founder)

Biospeediabiospeedia.comin 𝕏

BioSpeedia is a biotechnology company that develops and produces rapid lateral-flow diagnostic tests for infectious diseases, including tests for bacterial meningitis and SARS-CoV-2.

BiotechHealthtechMedical Devices

Evelyne Begaud(Co-founder & President)Yves Germani(Co-founder & Chief Scientific Officer)

Blackrock Neurotechblackrockneurotech.comin 𝕏

Blackrock Neurotech develops a neurotechnology platform, including brain-computer interface systems, aimed at improving patient lives and treating neurological conditions.

BiotechDeep TechMedical Devices

Florian Solzbacher(Co-Founder & CSO)Marcus Gerhardt(Co-Founder & CEO)Thomas Thiele(CFO)Christian Angermayer(Co-Chairman)Tim Sievers(Co-Chairman)

Exeliom Biosciencesexeliombio.com

Exeliom Biosciences is a biotechnology company developing biotherapies, with work in areas such as inflammatory bowel disease (Crohn's and colitis).

BiotechDeep TechDigital HealthMedical DevicesParis, FR

Harry Sokol(Scientific Co-founder)

GPN Vaccinesgpnvaccines.com

Invicta Medicalinvictamedical.com

Okeirookeiro.comin

Okeiro is a medical platform using predictive algorithms to monitor transplant and chronic disease patients.

AI & Machine LearningDigital HealthMedical Devices

Opportunistic North America Early Stageprecisionneuro.ioin 𝕏

Synchronsynchron.comin 𝕏May 2021

Synchron develops brain-computer interface technology delivered via catheter to restore or improve motor and cognitive function in people with impairment or decline.

BiotechDeep TechMedical DevicesCampbell, US

Thomas James Oxley(Executive Officer, Director)Martin Dieck(Director)Nicholas Opie(Director)Rahul Sharma(Director)

BoardAlex Morgan(Director)

Portfolio news

latest coverage across their companies

Synchron raises $200M to prepare for brain computer interface launch | MedTech Dive

Synchron · medtechdive.com · Nov 7, 2025

Frequently asked questions

What stage does Forepont Capital Partners invest at?: Forepont Capital Partners invests at the Pre-Seed, Seed, Series A, Series B, Series C, Late Stage stages.
What sectors does Forepont Capital Partners focus on?: Forepont Capital Partners focuses on AI & Machine Learning, Biotech, Deep Tech, Defense Tech, EdTech, Healthtech, Medical Devices.
Where is Forepont Capital Partners located?: Forepont Capital Partners is headquartered in New York, US.
Does Forepont Capital Partners lead rounds?: Yes, Forepont Capital Partners leads investment rounds.

Images

Similar investors

Olive Tree Capital

Olive Tree Capital invests in technology and life sciences companies, backing entrepreneurs across healthcare, fintech, enterprise, AI/ML, and frontier technology sectors.

B Capital Group

B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.

$10M – $50M

DCVC (Data Collective)

DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.

$5M – $25M

Basecamp Fund

A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.

$100K – $10M

LIFTT

LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.